Company news
Purple Biotech Ltd. (TASE:PPBT) news
Purple Biotech Ltd. news releases on 6ix. Latest, Apr 27, 2026: Purple Biotech Announces New Data from CAPTN-3 Platform Tri-specific IM1240
Press releases & updates
Purple Biotech Announces New Data from CAPTN-3 Platform Tri-specific IM1240
April 27, 2026
Purple Biotech Establishes Scientific Advisory Board to Support Development of CAPTN-3 Tri-Specific Antibody Platform
April 23, 2026
Purple Biotech Announces AI Collaboration with Converge Bio to Accelerate Development of its Next-Generation Tri-Specific Antibody Platform
March 25, 2026
Purple Biotech Regains Compliance with Nasdaq
March 17, 2026
Purple Biotech Announces CEO Transition
March 13, 2026
Purple Biotech Announces Plan to Implement ADS Ratio Change
February 25, 2026
Purple Biotech Achieves Toxicology Milestone Demonstrating an Expanded Therapeutic Window for CAPTN-3 Platform Tri-specific Antibody, IM1240
January 7, 2026
Purple Biotech Reports Positive New Preclinical Data Demonstrating Multi-Arm Anti-Tumor Activity Across Two CAPTN-3 Tri-Specific Antibodies at ESMO Immuno-Oncology Congress 2025
December 11, 2025
Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress
December 4, 2025
Purple Biotech Reports Third Quarter 2025 Financial Results and Provides Business Update
November 14, 2025
Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform
October 29, 2025
Purple Biotech Receives Intention to Grant a European Patent Covering NT219 Combinations with Immunotherapies or MEK Inhibitors to Overcome Tumor Resistance
September 10, 2025
Purple Biotech Announces Closing of Up To $18 Million Public Offering $6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants
September 5, 2025
Purple Biotech Announces Pricing of Up To $18 Million Public Offering
September 4, 2025
Purple Biotech Announces New Data Supporting the Unique Design of CAPTN-3 Tri-Specific Antibody IM1240 in Collaboration with the Icahn School of Medicine at Mount Sinai
September 4, 2025
Purple Biotech Expands CAPTN-3 Portfolio with IM1305, a Novel Tri-Specific Antibody Targeting TROP2
September 3, 2025
Purple Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
August 27, 2025
Purple Biotech Reports Second Quarter 2025 Financial Results
August 6, 2025
Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025
July 23, 2025
Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress
June 23, 2025
Purple Biotech Announces Initiation of Phase 2 Study of NT219 in Patients with Head and Neck Cancer
June 17, 2025
Purple Biotech Announces Poster Presentation at EACR 2025 on its Novel CAPTN-3 Tri-Specific Antibody Platform
June 4, 2025
Purple Biotech Reports First Quarter 2025 Financial Results
May 21, 2025
Purple Biotech Appoints Shai Lankry as Chief Financial Officer
May 12, 2025
Purple Biotech Reports Final Data from Phase 2 Study of CM24 in Pancreatic Cancer Patients at AACR 2025 Annual Meeting: Improved Outcomes and Significant Efficacy in Biomarker-Enriched Subgroups
April 30, 2025
Purple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck Cancers
April 28, 2025
Purple Biotech Announces Publication in the Neuro Oncology Journal Demonstrating the Potential of NT219 to Suppress Brain Metastasis of Colorectal Cancer
April 16, 2025
Purple Biotech to Participate in Panel Discussion at Canaccord Genuity Horizons in Oncology Virtual Conference on April 7, 2025
April 1, 2025
Purple Biotech Announces Three Posters Accepted for Presentation at the 2025 American Association for Cancer Research Meeting
March 28, 2025
Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results
March 10, 2025
Purple Biotech Granted New U.S. Patent for NT219 in Combination with EGFR Antibody Therapy, Enhancing Global IP Protection in Major Markets
March 5, 2025
Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial
February 18, 2025